1. Home
  2. NGVC vs OMER Comparison

NGVC vs OMER Comparison

Compare NGVC & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Natural Grocers by Vitamin Cottage Inc.

NGVC

Natural Grocers by Vitamin Cottage Inc.

HOLD

Current Price

$24.90

Market Cap

744.4M

ML Signal

HOLD

Logo Omeros Corporation

OMER

Omeros Corporation

HOLD

Current Price

$12.52

Market Cap

628.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NGVC
OMER
Founded
1955
1994
Country
United States
United States
Employees
N/A
N/A
Industry
Food Chains
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
744.4M
628.9M
IPO Year
2012
2009

Fundamental Metrics

Financial Performance
Metric
NGVC
OMER
Price
$24.90
$12.52
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$32.50
AVG Volume (30 Days)
271.1K
4.4M
Earning Date
02-05-2026
11-13-2025
Dividend Yield
2.37%
N/A
EPS Growth
36.05
N/A
EPS
2.00
N/A
Revenue
$1,330,836,000.00
N/A
Revenue This Year
$7.83
N/A
Revenue Next Year
$6.97
N/A
P/E Ratio
$12.67
N/A
Revenue Growth
7.19
N/A
52 Week Low
$23.47
$2.95
52 Week High
$61.22
$17.65

Technical Indicators

Market Signals
Indicator
NGVC
OMER
Relative Strength Index (RSI) 41.61 50.47
Support Level $23.47 $11.85
Resistance Level $25.95 $16.14
Average True Range (ATR) 0.89 1.62
MACD 0.25 -0.37
Stochastic Oscillator 51.40 43.31

Price Performance

Historical Comparison
NGVC
OMER

About NGVC Natural Grocers by Vitamin Cottage Inc.

Natural Grocers by Vitamin Cottage Inc operates natural and organic grocery and dietary supplement stores. It offers the following product categories, natural and organic food, dietary supplements, natural body care, household, pet care products, books and handouts. The Company has a single reporting segment, natural and organic retail stores, through which business are conducted. The company generates the majority of its revenue from grocery products and dietary supplements and rest from other products.

About OMER Omeros Corporation

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

Share on Social Networks: